

Prostate Cancer Diagnostics Market - 2022-2031

<https://marketpublishers.com/r/PE4A77B823D8EN.html>

Date: November 2025

Pages: 223

Price: US\$ 2,999.00 (Single User License)

ID: PE4A77B823D8EN

Abstracts

The Prostate Cancer Diagnostics Market was valued at US\$ 5.1 billion in 2022 and is anticipated to reach US\$ 11.6 billion by 2031, at a CAGR of 0.111 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Prostate Cancer Diagnostics Market.

This report delivers a comprehensive overview of the Prostate Cancer Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Prostate Cancer Diagnostics Market. The Prostate Cancer Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

Prostate Cancer Diagnostics Market Scope:

By Test Type

Digital Rectal Exam

PSA Blood Test

Biopsy

Genetic Testing

Imaging Tests

Others

By Cancer Type

Benign Prostate Hyperplasia

Prostatic Adenocarcinoma

Small Cell Carcinoma

Ductal prostate cancer

Others

By Stage

I

II

III

IV

By End User

Cancer Centers

Specialty Clinics

Others

Key Players

Myriad Genetics, Inc.

Quanterix Corporation

MDx Health

Siemens Healthineers

F. Hoffman-La Roche AG

OPKO Health, Inc

Thermo Fisher Scientific Inc.

Cellanix Diagnostics Inc.

MiR Scientific LLC

Proteomedix

Major Highlights

This report delivers a comprehensive overview of the Prostate Cancer Diagnostics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Prostate Cancer Diagnostics Market. The Prostate Cancer Diagnostics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Test Type
- 3.2. Snippet by Cancer Type
- 3.3. Snippet by Stage
- 3.4. Snippet by End User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Pipeline products
 - 4.1.1.2. Improvements in Diagnosis with the Integration of Artificial Intelligence
 - 4.1.2. Restraints
 - 4.1.2.1. Complications related to Biopsy procedures
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID
 - 6.1.2. Scenario During COVID
 - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY TEST TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
 - 7.1.2. Market Attractiveness Index, By Test Type
- 7.2. Digital Rectal Exam
- 7.3. PSA Blood Test
- 7.4. Biopsy
 - 7.4.1. Prostate Biopsy
 - 7.4.2. Transrectal Biopsy
 - 7.4.3. Transperineal Biopsy
 - 7.4.4. Lymph node Biopsy
- 7.5. Genetic Testing
- 7.6. Imaging Tests
 - 7.6.1. Transrectal Ultrasound (TRUS)
 - 7.6.2. Magnetic Resonance Imaging (MRI)
 - 7.6.3. Nuclear Imaging
- 7.7. Others

8. BY CANCER TYPE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 8.1.2. Market Attractiveness Index, By Cancer Type
- 8.2. Benign Prostate Hyperplasia
- 8.3. Prostatic Adenocarcinoma
- 8.4. Small Cell Carcinoma
- 8.5. Ductal prostate cancer
- 8.6. Others

9. BY STAGE

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

9.1.2. Market Attractiveness Index, By Stage

9.2. I

9.3. II

9.4. III

9.5. IV

10. BY END USER

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10.1.2. Market Attractiveness Index, By End User

10.2. Cancer Centers

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

10.3. Specialty Clinics

10.4. Others

11. BY REGION

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.7.1. Germany
 - 11.3.7.2. UK
 - 11.3.7.3. France
 - 11.3.7.4. Italy
 - 11.3.7.5. Spain
 - 11.3.7.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.7.1. Brazil
 - 11.4.7.2. Argentina
 - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.6.1. China
 - 11.5.6.2. India
 - 11.5.6.3. Japan
 - 11.5.6.4. Australia
 - 11.5.6.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction

- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. Myriad Genetics, Inc.
 - 13.1.1. Company Overview
 - 13.1.2. Product Type Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. Quanterix Corporation
- 13.3. MDx Health
- 13.4. Siemens Healthineers
- 13.5. F. Hoffman-La Roche AG
- 13.6. OPKO Health, Inc
- 13.7. Thermo Fisher Scientific Inc.
- 13.8. Cellanyx Diagnostics Inc.
- 13.9. MiR Scientific LLC
- 13.10. Proteomedix (*LIST NOT EXHAUSTIVE)

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Prostate Cancer Diagnostics Market - 2022-2031

Product link: <https://marketpublishers.com/r/PE4A77B823D8EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE4A77B823D8EN.html>